Kantarjian HM - Search Results

1

Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.

Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ. Hochhaus A, et al. Among authors: kantarjian hm. J Cancer Res Clin Oncol. 2013 Dec;139(12):1985-93. doi: 10.1007/s00432-013-1529-7. Epub 2013 Sep 22. J Cancer Res Clin Oncol. 2013. PMID: 24057647 Free PMC article. Clinical Trial.

2

Biology and treatment of chronic myelogenous leukemia.

Giles FJ, Kantarjian HM. Giles FJ, et al. Among authors: kantarjian hm. Oncology (Williston Park). 1997 Sep;11(9):1295-300; discussion 1302-10. Oncology (Williston Park). 1997. PMID: 9306419

3

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.

Vey N, Kantarjian H, Tran H, Beran M, O'Brien S, Bivins C, Giles F, Cortes J, Cheson B, Arbuck S, Estey E. Vey N, et al. Ann Oncol. 1999 May;10(5):577-83. doi: 10.1023/a:1026406920321. Ann Oncol. 1999. PMID: 10416008 Free article. Clinical Trial.

4

Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.

Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M. Estey EH, et al. Blood. 1999 Oct 1;94(7):2230-5. Blood. 1999. PMID: 10498593 Free article. Clinical Trial.

5

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.

Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ. Thomas DA, et al. Cancer. 1999 Oct 1;86(7):1216-30. doi: 10.1002/(sici)1097-0142(19991001)86:7<1216::aid-cncr17>3.0.co;2-o. Cancer. 1999. PMID: 10506707 Clinical Trial.

6

Phase I study of liposomal daunorubicin in patients with acute leukemia.

Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H. Cortes J, et al. Invest New Drugs. 1999;17(1):81-7. doi: 10.1023/a:1006216001681. Invest New Drugs. 1999. PMID: 10555126 Clinical Trial.

7

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.

Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Beran M, et al. J Clin Oncol. 1999 Sep;17(9):2819-30. doi: 10.1200/JCO.1999.17.9.2819. J Clin Oncol. 1999. PMID: 10561358 Clinical Trial.

8

Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.

Kaban K, Kantarjian H, Talpaz M, O'Brien S, Cortes J, Giles FJ, Pierce S, Albitar M. Kaban K, et al. Cancer. 2000 Feb 1;88(3):570-6. doi: 10.1002/(sici)1097-0142(20000201)88:3<570::aid-cncr12>3.0.co;2-i. Cancer. 2000. PMID: 10649249

9

The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.

Vey N, Giles FJ, Kantarjian H, Smith TL, Beran M, Jeha S. Vey N, et al. Clin Cancer Res. 2000 Feb;6(2):731-6. Clin Cancer Res. 2000. PMID: 10690560

10

Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.

Cortes J, Estey E, Beran M, O'Brien S, Giles F, Koller C, Keating M, Kantarjian H. Cortes J, et al. Leuk Lymphoma. 2000 Feb;36(5-6):479-84. doi: 10.3109/10428190009148395. Leuk Lymphoma. 2000. PMID: 10784392 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,381 results

Search Page